Medical devices, healthcare technology and the business of care
PMA SUPPLEMENT · P250029/S003

SimpleScreen CRC

Freenome, LLC · Decision date Oct 27, 2026

MEDTECHLEDGER EXPLANATIONP250029/S003

What did the FDA decide?

The FDA record for P250029/S003 describes a 30-day notice supplement to PMA P250029 for SimpleScreen CRC, submitted by Freenome, LLC. The stated purpose is approval of supplier reagent manufacturing and Quality Control changes, filed under the reason Process Change - Manufacturer/Sterilizer/Packager/Supplier. The device category is listed as a system for colorectal neoplasia DNA methylation and hemoglobin detection.

The identifier establishes this as a supplement to an existing PMA, not an approval of the whole SimpleScreen CRC system. The source gives only the purpose statement for the supplier reagent manufacturing and quality control changes; it does not identify which reagent, supplier, or specific quality control parameters changed, nor does it provide data on safety or clinical performance. Those details are absent from the supplied record.

Regulatory and clinical conclusions beyond this descriptive paraphrase would go beyond the source. The notice's reported purpose should not be read as independent evidence of analytical validity, safety, or clinical effectiveness.

FDA approval order statement

approval of supplier reagent manufacturing and Quality Control changes.
Regulatory pathway
PMA supplement
Supplement type
30-Day Notice
Clinical specialty
Medical Genetics
Decision date
Oct 27, 2026
FDA change category
Process Change - Manufacturer/Sterilizer/Packager/Supplier

FDA source record · MedtechLedger’s explanation describes the recorded change.

Regulatory record facts

Identifier
P250029/S003
Regulatory pathway
PMA supplement
Applicant
Freenome, LLC
Product code
PHP
Decision code
OK30
Decision date
Oct 27, 2026
Source update
Nov 9, 2026
Original record
Open FDA source record

About this medical device

FDA device category: System, colorectal neoplasia, DNA methylation and hemoglobin detection.

Applicant
Freenome, LLC
Product code
PHP
FDA device class
3

For the original device and its historical approval scope, see PMA P250029. Subsequent supplements may change the device or its indications.

FDA decision timeline

  1. P250029 · Original PMA

    SimpleScreen CRC

  2. P250029/S003 received

    Application receipt date recorded by FDA.

  3. P250029/S003 · FDA decision

    30-Day Notice

Timeline entries are records held by MedtechLedger for P250029. View FDA’s full supplement list.

Related devices and submissions

Same PMA: P250029

Product / regulatory recordCompanyPathwayDecision dateSource
Freenome, LLCPMA approvalJul 24, 2026FDA

Explore the linked device profile

Other records with product code PHP

Product / regulatory recordCompanyPathwayDecision dateSource
ShieldP230009/S021
Guardant Health, Inc.PMA supplementOct 5, 2026FDA
ShieldP230009/S020
Guardant Health, Inc.PMA supplementSep 16, 2026FDA
ShieldP230009
Guardant Health, Inc.PMA approvalJul 26, 2024FDA

A shared product code identifies a classification relationship; it does not establish clinical equivalence.

Regulatory context

A PMA supplement records a change to a device with an existing premarket approval. The supplement’s approval applies to the change described in that submission.

Read our guide to FDA clearance and approval · FDA’s explanation of this pathway

Manufacturer intelligence

Freenome, LLC

Headquarters
Not reported
Brand website
Not reported
FDA applicant address
Bldg. 1, 3300 Marina Blvd., Brisbane, CA, 94005

Sources and methodology

FDA fields and approval-order wording are presented as source information. MedtechLedger explanations are identified separately and describe the scope of the recorded decision. Indications from an original PMA are historical unless confirmed against subsequent labeling and supplements.

How we use FDA records